{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:33Z","timestamp":1789135953406,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"This study was funded by Medical Science Research Project of Hebei Provincial Health Commission","award":["Grant\/Award Numbers: 20231009"],"award-info":[{"award-number":["Grant\/Award Numbers: 20231009"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The concentration of antiseizure medications in vivo has a significant influence on therapeutic and adverse effects. To use antiseizure medications safely and rationally, it is crucial to establish a method of measuring their blood concentration, provide individualized medication guidance to patients, and avoid adverse effects through therapeutic drug monitoring. Therefore, we developed a high-performance liquid chromatography\u2013tandem mass spectrometry (HPLC-MS\/MS) method for the rapid detection of antiseizure medication concentrations in blood and applied it to the monitoring of clinical antiseizure medication therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A Waters HPLC-ESI TQ-D with a Waters BEH C18 column (50 \u00d7 2.1 mm, 1.7 \u00b5m) was used; the blood samples were injected after protein precipitation in 50% methanol in water, and the analysis was conducted within 3.5 minutes. The ion source for mass spectrometry was an electrospray ionization source with the multiple ion reaction monitoring mode. An isotope standard was selected as the internal standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The linearity of each epileptic drug was good in the studied concentration range (R2 &gt; 0.9930), and the lower limit of quantification was 0.01\u20138.00 mcg\/mL, with intraday and interday precision less than 15.00%. The recoveries of the method ranged from 91.86% to 113.97%, and the stability of the method was good and unaffected by matrix effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The established LC-MS\/MS method for the determination of antiseizure medication concentration was characterized by a simple operation procedure, short analysis time, high sensitivity, and good accuracy, providing a simple and reliable assay for the monitoring of antiseizure medication therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001434","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:04:12Z","timestamp":1767762252000},"page":"644-650","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Three Quantification Methods for Monitoring Twelve Antiseizure Medications in Human Plasma by LC-MS\/MS"],"prefix":"10.1097","volume":"48","author":[{"given":"Donghan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"},{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"},{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health;"},{"name":"The First Hospital of Hebei Medical University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyao","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"},{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health;"},{"name":"The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, the First Hospital of Hebei Medical University;"},{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health;"},{"name":"The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13760-019-01120-8","article-title":"The current and emerging therapeutic approaches in drug-resistant epilepsy management","volume":"119","author":"Mehdizadeh","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League against Epilepsy: position paper of the ILAE Commission for Classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1474-4422(21)00023-5","article-title":"Epilepsy in China: major progress in the past two decades","volume":"20","author":"Ding","year":"2021","journal-title":"Lancet Neurol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: an update","volume":"67","author":"B\u0142aszczyk","year":"2015","journal-title":"Pharmacol Rep"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"107568","DOI":"10.1016\/j.vascn.2024.107568","article-title":"Evaluation of 4 quantification methods for monitoring 16 antidepressant drugs and their metabolites in human plasma by LC-MS\/MS","volume":"130","author":"Wang","year":"2024","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/epd2.20069","article-title":"Pharmacological aspects of antiseizure medications: from basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring","volume":"25","author":"Johannessen Landmark","year":"2023","journal-title":"Epileptic Disord"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0021-9673(00)99259-8","article-title":"Simultaneous gas chromatographic analysis for the four commonly used antiepileptic drugs in serum","volume":"128","author":"Abraham","year":"1976","journal-title":"J Chromatogr"},{"key":"R15-20260911","first-page":"87","article-title":"Restricted-access media high pressure liquid chromatography vs fluorescence polarization immunoassay for analysis of carbamazepine in human plasma","volume":"23","author":"Ma","year":"2002","journal-title":"Acta Pharmacol Sin"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0731-7085(03)00525-9","article-title":"Simultaneous separation and quantitation of four antiepileptic drugs-a study with potential for use in patient drug level monitoring","volume":"34","author":"Manoj Babu","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FTD.0b013e3181678ecb","article-title":"High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry","volume":"30","author":"Subramanian","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jat\/bku070","article-title":"Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases","volume":"38","author":"Deeb","year":"2014","journal-title":"J Anal Toxicol"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","volume":"26","author":"Shibata","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"124143","DOI":"10.1016\/j.jchromb.2024.124143","article-title":"Simultaneous quantification of 11 antiepileptic drugs using limited isotope-labeled internal standards in LC-MS\/MS: an accuracy assessment","volume":"1240","author":"Abady","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2015.10.016","article-title":"Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of antidepressant and anxiolytic drugs in neonatal meconium and maternal hair","volume":"118","author":"Pichini","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.talanta.2019.01.112","article-title":"Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS\/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation","volume":"198","author":"Koller","year":"2019","journal-title":"Talanta"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1373\/49.7.1041","article-title":"Ion suppression in mass spectrometry","volume":"49","author":"Annesley","year":"2003","journal-title":"Clin Chem"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"105943","DOI":"10.1016\/j.ijantimicag.2020.105943","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations","volume":"55","author":"Xie","year":"2020","journal-title":"Int J Antimicrob Agents"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:44Z","timestamp":1789135244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001434","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}